Vilija G Jokubaitis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4283306/publications.pdf

Version: 2024-02-01

73 papers	3,421 citations	136740 32 h-index	149479 56 g-index
76 all docs	76 docs citations	76 times ranked	3220 citing authors

#	Article	IF	Citations
1	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
2	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	1.7	3
3	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	1.4	7
4	The MSBase pregnancy, neonatal outcomes, and womenâ€™s health registry. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110091.	1.5	6
5	High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199891.	1.5	9
6	Treatment of Women with Multiple Sclerosis Planning Pregnancy. Current Treatment Options in Neurology, 2021, 23, 11.	0.7	43
7	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
8	004â€…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
9	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.5	54
10	Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders. International Journal of MS Care, 2021, 23, 114-118.	0.4	4
11	Epigenome-wide association studies: current knowledge, strategies and recommendations. Clinical Epigenetics, 2021, 13, 214.	1.8	62
12	Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 696-705.	1.4	10
13	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	1.4	52
14	The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. Neurotherapeutics, 2020, 17, 1768-1784.	2.1	15
15	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. JAMA Neurology, 2020, 77, 1496.	4.5	21
16	Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. British Journal of Pharmacology, 2020, 177, 4113-4133.	2.7	15
17	Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093616.	1.5	58
18	MS, pregnancy and COVID-19. Multiple Sclerosis Journal, 2020, 26, 1137-1146.	1.4	10

#	Article	IF	Citations
19	Regarding: Nicotinic acetylcholine receptors Î±7 and Î±9 modify tobacco smoke risk for multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852096994.	1.4	0
20	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 44, 102241.	0.9	21
21	Increased risk of cervical dysplasia in females with autoimmune conditionsâ€"Results from an Australia database linkage study. PLoS ONE, 2020, 15, e0234813.	1.1	15
22	MSCOVID19: Using social media to achieve rapid dissemination of health information. Multiple Sclerosis and Related Disorders, 2020, 45, 102338.	0.9	17
23	Family planning is the second most relevant factor for treatment decisions after disease activity â€“ Commentary. Multiple Sclerosis Journal, 2020, 26, 644-644.	1.4	0
24	OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. Multiple Sclerosis and Related Disorders, 2020, 40, 101984.	0.9	3
25	Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. Life Science Alliance, 2020, 3, e202000650.	1.3	22
26	Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2020, 94, 455-456.	1.5	0
27	Pregnancy and multiple sclerosis: Clinical effects across the lifespan. Autoimmunity Reviews, 2019, 18, 102360.	2.5	23
28	Introducing the International Women in Multiple Sclerosis network. Lancet Neurology, The, 2019, 18, 521.	4.9	5
29	Family planning, antenatal and post partum care in multiple sclerosis: a review and update. Medical Journal of Australia, 2019, 211, 230-236.	0.8	16
30	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	0.9	71
31	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	0.9	35
32	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
33	Genotype and Phenotype in Multiple Sclerosisâ€"Potential for Disease Course Prediction?. Current Treatment Options in Neurology, 2018, 20, 18.	0.7	9
34	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	1.4	37
35	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	1.4	36
36	028â€...Treating progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A12.1-A12.	0.9	0

#	Article	IF	Citations
37	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	4.5	20
38	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics Journal, 2017, 17, 312-318.	0.9	28
39	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
40	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	0.9	49
41	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
42	JC virus conversion rates in natalizumab treated patients: the melbourne longitudinal cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.15-e1.	0.9	0
43	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.5	38
44	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	1.4	18
45	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	3.7	94
46	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	3.7	281
47	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	0.8	33
48	A genetic basis for multiple sclerosis severity: Red herring or real?. Molecular and Cellular Probes, 2016, 30, 357-365.	0.9	20
49	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	2.8	158
50	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	1.4	34
51	Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor. Glia, 2015, 63, 1005-1020.	2.5	13
52	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	0.5	5
53	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	2.8	143
54	Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2015, 2, 479-491.	1.7	43

#	Article	IF	Citations
55	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	4.5	100
56	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	3.7	162
57	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	1.4	36
58	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	1.4	73
59	Ceruloplasmin geneâ€deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution. Journal of Neuroscience Research, 2014, 92, 732-742.	1.3	3
60	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.5	138
61	8.. Journal of Clinical Neuroscience, 2014, 21, 2035-2036.	0.8	0
62	Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. Journal of Clinical Investigation, 2014, 124, 5042-5056.	3.9	26
63	Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2013, 1, 32.	2.4	29
64	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	3.7	140
65	Microglial Function in MS Pathology. , 2013, , 47-70.		0
66	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS ONE, 2013, 8, e59694.	1.1	38
67	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 2012, 18, 974-982.	1.4	56
68	The Kurtzke EDSS rank stability increases 4â€…years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	0.9	37
69	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.3	35
70	Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism. PLoS ONE, 2012, 7, e47379.	1.1	24
71	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	1.1	35
72	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	1.1	166

#	Article	IF	Citations
73	Gas6 Deficiency Increases Oligodendrocyte Loss and Microglial Activation in Response to Cuprizone-Induced Demyelination. Journal of Neuroscience, 2008, 28, 5195-5206.	1.7	114